Posted by Samy Goldfarb
December 18, 2013 at 10:49 AM
Topics: ISCO, human induced pluripotent stem cell
Posted by Samy Goldfarb
December 9, 2013 at 11:54 AM
International Stem Cell Corporation (ISCO:OTCQB), a biotechnology company developing novel stem cell-based therapies, announced the development of a new method for the derivation of human induced pluripotent stem cells (iPS) that utilizes a novel protein-based reprogramming process. The Company believes that the new method is a safer and more efficient alternative to older iPS reprogramming techniques, and represents a step forward in the ability to use iPS clinically.
Topics: ISCO, human induced pluripotent stem cell
We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.
CONTACT INFORMATION
Phone: (212) 851-6685